CPT code 0048U identifies the MSK–IMPACT™ proprietary laboratory assay, a targeted next‑generation DNA sequencing panel for detecting somatic mutations in formalin‑fixed, paraffin‑embedded tumor tissues from solid organ cancers. As a PLA code tied to a single laboratory/manufacturer, 0048U matters nationally because it standardizes reporting for a widely referenced commercial tumor profiling test and affects coding consistency, payer policy development, and claims processing for somatic molecular diagnostics.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the assay, the service setting, and how the PLA designation shapes coding practice. The publication presents national benchmarks for coding and coverage where available, summarizes relevant payer policy trends and reimbursement considerations for proprietary tumor profiling assays, and situates 0048U within the clinical context of precision oncology and somatic mutation testing.

This summary is intended to inform clinicians, laboratory billing staff, and policy analysts about the code's scope, common payer coverage environment, and the types of benchmarks and policy updates addressed in the full publication.